RAPT Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAPT research report →
Companywww.rapt.com
RAPT Therapeutics, Inc. , a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
- CEO
- Brian Russell Wong
- IPO
- 2019
- Employees
- 67
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $959.26M
- P/E
- -14.81
- P/S
- 0.00
- P/B
- 10.29
- EV/EBITDA
- -8.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.81%
- ROIC
- -72.87%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-129,865,000 · -11.19%
- EPS
- $-25.49 · -4.58%
- Op Income
- $-136,101,000
- FCF YoY
- 15.03%
Performance & Tape
- 52W High
- $58.02
- 52W Low
- $5.67
- 50D MA
- $49.05
- 200D MA
- $26.91
- Beta
- 0.44
- Avg Volume
- 2.34M
Get TickerSpark's AI analysis on RAPT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 3, 26 | Lyons-Williams Lori | other | 4,956 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 2,813 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 1,063 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 1,618 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 4,561 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 32,229 |
| Mar 3, 26 | GRAY MARY ANN | other | 4,956 |
| Mar 3, 26 | GRAY MARY ANN | sell | 2,813 |
| Mar 3, 26 | GRAY MARY ANN | sell | 498 |
| Mar 3, 26 | GRAY MARY ANN | sell | 938 |
Our RAPT Coverage
We haven't published any research on RAPT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RAPT Report →